Biofrontera (BFRI) vs CalciMedica (CALC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biofrontera (BFRI) has outperformed CalciMedica (CALC) over the past year, losing 28.4% versus a loss of 92.3%. Biofrontera is the larger company by market cap ($9.5 million vs $8.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | CALC |
|---|---|---|
| Share price | $0.53 | $1.26 |
| Market cap | $9.51M | $8.69M |
| 1-day change | -7.02% | +7.69% |
| YTD return | -7.02% | -96.18% |
| 1-year return | -28.38% | -92.34% |
| 5-year return | -99.66% | — |
| Forward P/E | 1.32 | — |
| EPS (TTM) | $-0.26 | $-4.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.70M | — |
| Revenue growth (YoY) | +11.75% | — |
| Net income (latest FY) | $-10.54M | $-29.56M |
| Operating margin | -27.21% | — |
| Net margin | -25.26% | — |
| 52-week high | $1.66 | $36.00 |
| 52-week low | $0.53 | $1.00 |
| Distance from 52-week high | -68.07% | -96.50% |
| Analyst consensus | none | none |
| Avg. price target upside | +1032.08% | +3868.25% |
| Average volume | 429.04K | 80.15K |
| Shares outstanding | 17.95M | 6.90M |
| Employees | 84 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed CALC by 64.0 percentage points over the past year.
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
BFRI vs CALC FAQ
Which is bigger, Biofrontera or CalciMedica?
Biofrontera (BFRI) is larger, with a market capitalization of $9.51M compared with $8.69M for CalciMedica (CALC).
Which stock has performed better over the past year, BFRI or CALC?
BFRI returned -28.38% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and CalciMedica in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.